Literature DB >> 8144552

Juvenile form of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). A C-terminal extension causes instability but increases catalytic efficiency of arylsulfatase B.

G Arlt1, D A Brooks, D Isbrandt, J J Hopwood, J Bielicki, T M Bradford, C A Bindloss-Petherbridge, K von Figura, C Peters.   

Abstract

A deficiency of the enzyme arylsulfatase B results in the lysosomal storage disorder Maroteaux-Lamy syndrome or mucopolysaccharidosis type VI. Severe, intermediate and mild forms of this autosomal recessively inherited disease can be clinically differentiated. To determine the molecular defect in a patient with the intermediate form of the disorder, DNA fragments generated from the patient's mRNA by reverse transcription and subsequent amplification by the polymerase chain reaction were subcloned and sequenced. The mRNA transcribed from one allele contains a 244-base pair deletion causing a frameshift and a truncation of the open reading frame. The C-terminal third of the encoded mutant polypeptide has a nonsense sequence. This mutation is due to a deletion of exon 5 in this allele. A silent A to G transition at nucleotide 1191 was present in the same allele, and the second allele was characterized by a T to C transition at nucleotide 1600 causing a mutation of the translational stop codon to a glutamine codon (*534Q) and extending the encoded polypeptide by 50 amino acids. Stable expression of the *534Q allele in LTK- cells resulted in a mutant precursor 4 kDa larger than the wild-type precursor. The majority of the mutant precursor appears to be degraded before reaching the trans Golgi. This is consistent with an altered polypeptide structure, where a number of missing or masked epitopes were observed in an enzyme immunobinding assay using a panel of monoclonal antibodies. Immunoquantification analysis showed that epitopes were most likely masked, as missing epitopes could be reformed by binding the mutant protein to a polyclonal antibody of arylsulfatase B. It is suggested that the additional amino acids at the C terminus of the arylsulfatase B polypeptide induce a protein conformational change. *534Q mutant polypeptide escaping degradation is sorted to dense lysosomes. The mutant polypeptide has an approximately 9-fold higher catalytic efficiency than wild-type arylsulfatase B.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8144552

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  10 in total

1.  Processing of normal lysosomal and mutant N-acetylgalactosamine 4-sulphatase: BiP (immunoglobulin heavy-chain binding protein) may interact with critical protein contact sites.

Authors:  T M Bradford; M J Gething; R Davey; J J Hopwood; D A Brooks
Journal:  Biochem J       Date:  1999-07-01       Impact factor: 3.857

2.  Identification, expression, and biochemical characterization of N-acetylgalactosamine-4-sulfatase mutations and relationship with clinical phenotype in MPS-VI patients.

Authors:  T Litjens; D A Brooks; C Peters; G J Gibson; J J Hopwood
Journal:  Am J Hum Genet       Date:  1996-06       Impact factor: 11.025

3.  Identification of CRYM as a candidate responsible for nonsyndromic deafness, through cDNA microarray analysis of human cochlear and vestibular tissues.

Authors:  Satoko Abe; Toyomasa Katagiri; Akihiko Saito-Hisaminato; Shin-ichi Usami; Yasuhiro Inoue; Tatsuhiko Tsunoda; Yusuke Nakamura
Journal:  Am J Hum Genet       Date:  2002-12-06       Impact factor: 11.025

4.  Two site-directed mutations abrogate enzyme activity but have different effects on the conformation and cellular content of the N-acetylgalactosamine 4-sulphatase protein.

Authors:  D A Brooks; D A Robertson; C Bindloss; T Litjens; D S Anson; C Peters; C P Morris; J J Hopwood
Journal:  Biochem J       Date:  1995-04-15       Impact factor: 3.857

5.  Molecular Analysis of Turkish Maroteaux-Lamy Patients and Identification of One Novel Mutation in the Arylsulfatase B (ARSB) Gene.

Authors:  Alessandra Zanetti; Neslihan Onenli-Mungan; Nursel Elcioglu; Mehmet Nuri Ozbek; Deniz Kör; Elisabetta Lenzini; Maurizio Scarpa; Rosella Tomanin
Journal:  JIMD Rep       Date:  2013-11-16

6.  Prevalence of anti-adeno-associated virus serotype 8 neutralizing antibodies and arylsulfatase B cross-reactive immunologic material in mucopolysaccharidosis VI patient candidates for a gene therapy trial.

Authors:  Rita Ferla; Pamela Claudiani; Marco Savarese; Karen Kozarsky; Rossella Parini; Maurizio Scarpa; Maria Alice Donati; Giovanni Sorge; John J Hopwood; Giancarlo Parenti; Simona Fecarotta; Vincenzo Nigro; Hatice Serap Sivri; Ans Van Der Ploeg; Generoso Andria; Nicola Brunetti-Pierri; Alberto Auricchio
Journal:  Hum Gene Ther       Date:  2015-03       Impact factor: 5.695

7.  Molecular findings of Colombian patients with type VI mucopolysaccharidosis (Maroteaux-Lamy syndrome).

Authors:  Gustavo Adolfo Giraldo; Paola Ayala-Ramírez; Juan Carlos Prieto; Reggie García-Robles; Johanna Carolina Acosta
Journal:  Meta Gene       Date:  2015-12-23

8.  Mutational analysis of ARSB gene in mucopolysaccharidosis type VI: identification of three novel mutations in Iranian patients.

Authors:  Nasrin Malekpour; Rahim Vakili; Tayebeh Hamzehloie
Journal:  Iran J Basic Med Sci       Date:  2018-09       Impact factor: 2.699

9.  Twenty patients including 7 probands with autosomal dominant cutis laxa confirm clinical and molecular homogeneity.

Authors:  Smail Hadj-Rabia; Bert L Callewaert; Emmanuelle Bourrat; Marlies Kempers; Astrid S Plomp; Valerie Layet; Deborah Bartholdi; Marjolijn Renard; Julie De Backer; Fransiska Malfait; Olivier M Vanakker; Paul J Coucke; Anne M De Paepe; Christine Bodemer
Journal:  Orphanet J Rare Dis       Date:  2013-02-25       Impact factor: 4.123

10.  Mucopolysaccharidosis type VI phenotypes-genotypes and antibody response to galsulfase.

Authors:  Marion M Brands; Marianne Hoogeveen-Westerveld; Marian A Kroos; Willemieke Nobel; George J Ruijter; Lale Özkan; Iris Plug; Daniel Grinberg; Lluïsa Vilageliu; Dicky J Halley; Ans T van der Ploeg; Arnold J Reuser
Journal:  Orphanet J Rare Dis       Date:  2013-04-04       Impact factor: 4.123

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.